Connect with us

Technology

Circulate Health announces exclusive partnership with Reborne to bring its advanced therapeutic plasma exchange protocols to UK for first time

Published

on

LONDON, June 25, 2026 /PRNewswire/ — Circulate Health and Reborne have today announced an exclusive partnership that will see Reborne become the first UK hospital to offer the American biotechnology company’s therapeutic plasma exchange (TPE) procedures. The agreement also marks Circulate Health’s first partnership in Europe.

TPE is a medical procedure in which blood plasma is separated from whole blood and replaced with a substitute fluid before being returned to the body. It is performed using FDA-cleared apheresis technology under clinical supervision and is an established procedure in conventional medicine. In the United States, Circulate Health delivers standardised TPE protocols within a structured longevity and healthspan-focused network of clinic partners. 

Circulate Health is a biotechnology company backed by Khosla Ventures and founded on research from the Buck Institute for Research on Aging.

Interest in TPE within longevity medicine reflects growing scientific attention on circulating factors in blood plasma and their potential link to ageing. This includes research into inflammatory proteins, glycan patterns, and environmental exposures such as microplastics. 

More broadly, it forms part of a growing emphasis on supporting longer periods of physical and cognitive function, with focus on extending mobility, resilience and quality of life. 

A leading US biotechnology platform

Circulate Health was founded on geroscience research by Eric Verdin, MD, President and CEO of the Buck Institute for Research on Aging. The company is led by Chief Executive Officer and co-founder Brad Younggren, MD, and blends expertise across clinical medicine, nursing leadership and healthcare operations.

In 2025, it raised a $12 million seed round led by Khosla Ventures, with participation from Scrum Ventures, Seaside Ventures and CSC Ventures, indicating growing investor interest in longevity-focused healthcare models.

The company publishes research on therapeutic plasma exchange and promotion of longevity in peer-review journals such as Aging Cell and The Clinical Journal of Apheresis. A recent publication reports, using multi-omic and epigenetic analysis, that therapeutic plasma exchange induces a salutary effect on important biomarkers of aging. Other peer-reviewed work explores elimination of circulating environmental toxins, including a study demonstrating the reduction of circulating microplastics in human patients, and the effect of plasma exchange on glycan-related biomarkers of aging. 

Healthspan and longevity medicine

Across healthcare, there is a shift in emphasis, from disease treatment to disease prevention with a focus on maintaining longer periods of sustained physical, cognitive and metabolic function. This transition has helped define the emerging field of healthspan-focused medicine, in which the emphasis is placed on resilience and physiological performance across longer lives. Rather than focusing solely on lifespan, longevity medicine is increasingly concerned with healthspan: the period of life spent in good health.

Circulate Health’s protocols are delivered in the US within structured clinical environments supported by skilled apheresis teams and standardised operational systems across multiple partner clinics.

Faye Mythen, consulting CEO at Reborne, said: “Our partnership with Circulate Health reflects a shared belief that longevity medicine should be held to the same standards as any serious science. Circulate has built something genuinely special: a network of practicing physicians working under strong clinical oversight, supported by research partnerships with leading institutions such as the Buck Institute. 

“Therapeutic plasma exchange has one of the strongest evidence trajectories in longevity medicine, and making it available through Reborne, alongside a team of this calibre, is exactly the kind of innovation we want to help bring to a wider audience.”

Brad Younggren, MD, Chief Executive Officer and Co-Founder of Circulate Health, said: “We’re entering a new era of longevity medicine where advances in diagnostics are giving us unprecedented insight into the factors that influence long-term health — from biological aging and inflammation to environmental exposures. 

“The opportunity now is to connect those insights to evidence-based interventions and measurable outcomes. Therapeutic Plasma Exchange is one of the emerging approaches being explored within this broader shift, and we’re excited to partner with Reborne to bring our structured TPE protocols, clinical expertise, and research-driven approach to patients in the UK.”

Notes to editors

About Reborne 

Reborne is London’s first private concierge longevity clinic and a CQC-licensed independent hospital. Based in Marylebone, it combines advanced diagnostics, functional medicine and physician-led preventive care within a regulated clinical setting, focused on supporting healthspan, vitality and long-term wellbeing.

About Circulate Health

Backed by Khosla Ventures, Circulate Health is a leading Therapeutic Plasma Exchange (TPE) company advancing healthspan through evidence-based protocols and clinical research, helping define the future of longevity therapeutics. Co-founded with Eric Verdin, MD, CEO of the Buck Institute for Research on Aging, Circulate is the first company to publish a single-blind, randomised, placebo-controlled human clinical trial demonstrating TPE’s measurable effects on biological age. Circulate’s standardised TPE protocols are delivered through a growing network of partner longevity clinics across the United States, supported by expert apheresis nurses and clinical operational infrastructure.

Photo – https://mma.prnewswire.com/media/2999972/Picture1.jpg
Logo – https://mma.prnewswire.com/media/3000042/6013553/Reborne_Logo.jpg
Logo – https://mma.prnewswire.com/media/2999971/6013398/Circulate_Logo.jpg

Media contacts :
Rohan Banerjee — Hawthorn Advisors;
rb.banerjee@hawthornadvisors.com | (+44) 7391 632 250 

Sarah Clarbour — Hawthorn Advisors; 
s.clarbour@hawthornadvisors.com | (+44) 4477 524 64195  

 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/circulate-health-announces-exclusive-partnership-with-reborne-to-bring-its-advanced-therapeutic-plasma-exchange-protocols-to-uk-for-first-time-302809805.html

SOURCE Reborne; Circulate Health

Continue Reading

Technology

TECNO Wins Two IFA Global Product Technology Innovation Awards for Modular Phone and Tonino Lamborghini TECNO TAURUS

Published

on

By

BERLIN, Sept. 5, 2026 /PRNewswire/ — TECNO, a global AI-driven innovative technology brand, achieved two IFA Global Product Technology Innovation Awards at IFA 2026:

Tonino Lamborghini TECNO TAURUS took the Miniaturized Gaming PC Technology Innovation Gold Award, standing out with its Italian aesthetics and exceptional performance in the compact body. The TECNO Modular Phone was honored with the Ultra-Slim Magnetic Modular Technology Innovation Gold Award, praised for its ultra-slim craftsmanship and unique modular magnetic technology.

These awards once again demonstrate TECNO’s sustained breakthroughs in product innovation and industry-leading craftsmanship in design excellence. The Global Product Technology Innovation Awards were established in 2014 by IDG, IFA, and DIHK to celebrate excellence across the global consumer electronics industry. The awards honor products that set new industry benchmarks and drive innovation through intelligent technology and user-centric design.

TECNO Modular Phone: The World’s Thinnest Modular Smartphone

At just 4.9mm, the TECNO Modular Phone is powered by proprietary Modular Magnetic Interconnection Technology. It combines a precision magnetic array with pogo-pin connectors, offering a flexible ecosystem for different needs. The host retains a 3000–4000mAh battery, while modules draw power directly for a snap-and-go experience. It also resolves the inherent conflict between rising AI computing demands and limited device space.

The technology has earned over 20 accolades from leading media, with CNET and Yanko Design naming it the Best of MWC 2026, and The Verge recognizing it as the Best Mobile Tech at MWC 2026.

Tonino Lamborghini TECNO TAURUS: One of the World’s Smallest Water-Cooling Gaming Mini-PCs

At around 6.36 liters, the panoramic transparent chassis of the Tonino Lamborghini TECNO TAURUS fuses iconic Italian design with raw engineering. Powered by the Intel® Core™ i9-13900HK and NVIDIA® GeForce RTX™ 5060 (614 AI TOPS, 145W TGP, DLSS 4), it achieves the pinnacle of performance, providing a high-fidelity gaming experience and high-efficiency AI workstation. The water-cooling system sustains peak frequencies, while 15 ports and WiFi 6E deliver connectivity. It was recognized with Yanko Design’s Best of MWC award.

In addition, TECNO made waves at IFA with the Next-Gen Bezelless Concept Phone featuring a revolutionary 0mm screen bezel, and the convertible laptop MEGABOOK T15 360 Pro. Relentlessly pushing the boundaries of design, performance, and AI innovation, TECNO is pioneering limitless possibilities for futuristic technology.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/tecno-wins-two-ifa-global-product-technology-innovation-awards-for-modular-phone-and-tonino-lamborghini-tecno-taurus-302870739.html

Continue Reading

Technology

Morpho UV Printer Unveiled at IFA with Hands-On Live Creation

Published

on

By

BERLIN, Sept. 5, 2026 /PRNewswire/ — Morpho, a company specializing in UV printing technology, is showcasing its first desktop UV printer at IFA 2026, Hall 17-196. Visitors are observing Morpho’s colorful, textured prints, and some have the opportunity to print on a range of blank materials provided.

Morpho’s desktop UV printer can print on a wide range of materials, including wood, glass, leather, metal, and more, delivering vivid colors and tactile textures for customized results. At IFA 2026, the booth attracted interest from creators, educators, and technology professionals, who gathered to watch live demonstrations.

Among those who have tried Morpho’s printer, three aspects are most frequently highlighted: print quality, the moving gantry design, and overall ease of use.

Visitors are first drawn to the prints, which feature precise color reproduction and finely detailed textile textures. With G7 Master ColorSpace certification, Morpho ensures consistent tones across different pieces. The same level of precision is evident in the raised textures created by the industrial-grade printhead, which builds fine layers of ink for detailed, tactile surfaces. The printhead maintains fast carriage motion speeds of up to 600mm/s while preserving precise detail.

Attendees have also noted the printer’s compact desktop footprint. With its moving gantry architecture—where the entire gantry moves along both axes—the printer offers a large, fully enclosed print chamber that accommodates various objects while remaining desktop-friendly.

First-time users have given positive feedback on Morpho’s usability. The integrated Stereo Vision Smart Alignment™ System quickly captures an object’s height and contours, while Morpho Studio’s guided workflows help users move from idea to print with minimal setup.

Morpho’s team shared that the program has been in development for several years, with the goal of making UV printers a practical tool for everyday creative use. Founder Mingyu “Brett” Wang, formerly Global VP of R&D at DJI, commented, “We communicate directly with our community, listen to feedback, and make fast improvements.”

Ahead of IFA, Morpho’s Kickstarter campaign surpassed $10 million in support from over 2,800 backers worldwide. The company is committed to further developing its proprietary core technology and delivering reliable engineering for creators, makers, and small businesses.

Visit Morpho’s website to learn more.

About Morpho: Morpho develops desktop UV printers that bring industrial-grade printing and coloring to everyday materials, enabling creators to turn almost any physical surface into a canvas for their ideas.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/morpho-uv-printer-unveiled-at-ifa-with-hands-on-live-creation-302870741.html

Continue Reading

Technology

Society of Robotic Surgery and Puma Venture Capital Announce Winners of SRS Shark Tank 2026

Published

on

By

Drive Medical claimed the top prize at the third annual SRS Shark Tank 2026, held during the Society of Robotic Surgery’s annual conference at the Diplomat Beach Resort in Hollywood, Florida. The event, a collaboration between SRS and Puma Venture Capital, once again showcased cutting-edge innovations in the digital and robotic surgery ecosystem and featured early-stage companies poised to transform minimally invasive care.

HOLLYWOOD, Fla., Sept. 5, 2026 /PRNewswire-PRWeb/ — Drive Medical claimed the top prize at the third annual SRS Shark Tank 2026, held during the Society of Robotic Surgery’s annual conference at the Diplomat Beach Resort in Hollywood, Florida. The event, a collaboration between SRS and Puma Venture Capital, once again showcased cutting-edge innovations in the digital and robotic surgery ecosystem and featured early-stage companies poised to transform minimally invasive care.

SRS Shark Tank 2026 featured presentations from nine innovative companies. Each had five minutes to pitch their technology and five minutes to engage in a Q&A session with a panel of esteemed judges, including top surgeons, investors, and medical device experts. Companies were evaluated on innovation, impact on healthcare, market potential, business model, and presentation.

Drive Medical earned the top honor for the Pollywog System, the first easy-to-use robotic endoscope integrated with artificial intelligence. The platform is designed to give physicians faster, safer access to the small bowel, allowing diagnosis and treatment to be completed in a single session rather than across multiple procedures.

DeepQure secured second place with HyperQure, the world’s first extravascular renal denervation system for resistant hypertension. Delivered laparoscopically, the device wraps the renal artery from the outside to achieve complete denervation while avoiding the vessel lining.

Microsure came in third with MUSA-3, a microsurgical robot that downscales and stabilizes a surgeon’s hand movements during open super-microsurgical procedures, including free flap, lymphatic, and peripheral nerve surgery. The system received CE mark approval earlier this year.

The strength of the 2026 field extended well beyond the podium: every one of the nine presenting companies was placed in the top three by at least one judge. Reveal Surgical presented optical imaging technology that characterizes tissue for tumor assessment during surgery, and Symphera demonstrated a laparoscopic system that lets surgeons switch instrument tips at the push of a button. Tioga Cardiovascular showed its transcatheter approach to mitral and tricuspid valve replacement.

CardioSentry presented an AI platform for autonomous cardiac ultrasound, and Nina Medical showcased a completely non-invasive treatment for benign prostatic hyperplasia. LITLab rounded out the slate with mobile, high-fidelity surgical training labs that travel to health systems and medtech companies to train clinical teams onsite. Together the group reflected an unusually broad and competitive slate, spanning robotics, imaging, structural heart, urology, and surgical education.

The 2026 judging panel included Steve Bell, Rob Morgan, Dr. Santiago Horgan, Dr. Erik B. Wilson, Scott Zinober, and Babak Tehranchi, and the event was co-chaired by Amit Hazan and Dr. Vipul Patel.

Participating companies included:

Microsure, Symphera, LITLab, Reveal Surgical, DeepQure, Drive Medical, Nina Medical, CardioSentry, and Tioga Cardiovascular.

About the Society of Robotic Surgery:

Founded in 2012, the Society of Robotic Surgery (SRS) is guided by the fundamental principles of education and collaboration as a means to tackle the complex issues of robotic surgery. The SRS’ membership includes more than 20,000 physicians of all disciplines from around the world whose mission is to share information related to multi-centric studies, database collection, fellowship training and funding support related to robotic surgery. The SRS is the only multi-specialty robotic surgery society in the world with an annual meeting that includes updates in more than a dozen medical sub-specialties along with state-of-the-art plenary sessions and hot topic courses.

About Puma Venture Capital:

Puma Venture Capital is an investment firm seeking to leverage its surgeon venture partners to invest in all aspects of physical intelligence across every medical procedure — to improve patient outcomes, lift labor productivity, and lower system costs.

Media Contact

Ryan Julison, Society of Robotic Surgery, 1 3213776877, ryanjulison@gmail.com

View original content:https://www.prweb.com/releases/society-of-robotic-surgery-and-puma-venture-capital-announce-winners-of-srs-shark-tank-2026-302869733.html

SOURCE Society of Robotic Surgery

Continue Reading

Trending